Multicenter experience with andexanet alfa for refractory pericardial bleeding during catheter ablation of atrial fibrillation.
Tarek ZghaibJohn D AllisonChristopher D BarrettJeffrey S ArklesBenjamin D'SouzaJeffrey LuebbertFermin GarciaE Kevin HeistWendy S TzouDavid CallansFrancis E MarchlinskiDavid S FrankelPublished in: Journal of cardiovascular electrophysiology (2023)
In patients on uninterrupted apixaban or rivaroxaban, who develop refractory pericardial bleeding during AF ablation, andexanet can achieve hemostasis thereby avoiding the need for emergent surgery. However, there is a risk of thromboembolism following administration.
Keyphrases
- atrial fibrillation
- catheter ablation
- left atrial
- left atrial appendage
- oral anticoagulants
- direct oral anticoagulants
- end stage renal disease
- heart failure
- percutaneous coronary intervention
- minimally invasive
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- cross sectional
- coronary artery bypass
- prognostic factors
- clinical trial
- patient reported outcomes
- coronary artery disease
- smoking cessation
- surgical site infection